ストックスクリーナーアプリを入手
153.95
0.96%
1.47
プレマーケット:
154.76
0.81
+0.53%
前日終値:
$152.48
開ける：
$153.25
24時間の取引高:
1.67M
Relative Volume:
0.95
時価総額：
$23.52B
収益：
$4.28B
当期純損益:
$1.26B
株価収益率:
19.50
EPS:
7.8957
ネットキャッシュフロー:
$943.00M
1週間 パフォーマンス:
+5.95%
1か月 パフォーマンス:
+11.88%
6か月 パフォーマンス:
+50.89%
1年 パフォーマンス:
+9.68%
1日の値動き範囲:
$152.95
$155.53
1週間の範囲:
$137.00
$155.53
52週間の値動き範囲:
$68.70
$155.53
Illumina Inc Stock (ILMN) Company Profile
ILMN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
153.95 | 23.30B | 4.28B | 1.26B | 943.00M | 7.8957 |
|
TMO
Thermo Fisher Scientific Inc
|
639.45 | 239.06B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
240.08 | 170.97B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
691.05 | 55.61B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
239.05 | 41.11B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
138.63 | 39.62B | 6.95B | 1.30B | 1.15B | 4.5696 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-12 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2025-07-11 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-04 | 繰り返されました | Citigroup | Neutral |
| 2025-02-28 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-02-10 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2025-02-07 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-12-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-11-12 | 再開されました | Morgan Stanley | Equal-Weight |
| 2024-10-17 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-08-28 | アップグレード | Argus | Hold → Buy |
| 2024-08-16 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | アップグレード | Barclays | Underweight → Equal Weight |
| 2024-08-14 | アップグレード | TD Cowen | Hold → Buy |
| 2024-07-10 | アップグレード | Citigroup | Neutral → Buy |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2024-01-16 | ダウングレード | HSBC Securities | Buy → Hold |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-14 | 開始されました | Stephens | Overweight |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-12-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-12-11 | アップグレード | Citigroup | Sell → Neutral |
| 2023-11-10 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | 開始されました | Bernstein | Underperform |
| 2023-07-05 | 再開されました | JP Morgan | Neutral |
| 2023-01-25 | ダウングレード | Argus | Buy → Hold |
| 2023-01-05 | 開始されました | Scotiabank | Sector Perform |
| 2022-12-12 | ダウングレード | Citigroup | Neutral → Sell |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-10-04 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | アップグレード | Evercore ISI | In-line → Outperform |
| 2022-08-25 | 開始されました | Credit Suisse | Neutral |
| 2022-07-13 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2022-01-18 | アップグレード | Stifel | Hold → Buy |
| 2022-01-11 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-01-07 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-06 | 再開されました | Piper Sandler | Overweight |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-08-19 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | アップグレード | Evercore ISI | Underperform → In-line |
| 2021-03-31 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | 開始されました | Barclays | Underweight |
| 2020-12-22 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | アップグレード | BTIG Research | Neutral → Buy |
| 2020-10-13 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-09-30 | 開始されました | Atlantic Equities | Overweight |
| 2020-09-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | ダウングレード | Stifel | Buy → Hold |
| 2020-09-22 | ダウングレード | UBS | Buy → Neutral |
| 2020-09-21 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-09-21 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-08-07 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2020-08-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-04-24 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-04-21 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | 開始されました | Wells Fargo | Underweight |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-11-15 | 開始されました | Stifel | Buy |
| 2019-10-25 | 開始されました | Guggenheim | Buy |
すべてを表示
Illumina Inc (ILMN) 最新ニュース
Universal Beteiligungs und Servicegesellschaft mbH Purchases 40,166 Shares of Illumina, Inc. $ILMN - MarketBeat
$4.5 Billion Whole Genome Sequencing Market Outlook, 2031 - GlobeNewswire
United States Agrigenomics Market | CAGR 8% | North America Leads - openPR.com
Former Illumina Executive Moves Into Quanterix’s Corner Office - Medical Product Outsourcing
Dubai Health embraces genomics to advance care and research - Illumina
Next Generation Sequencing Market Size to Worth USD 103.24 Bn by 2035 - GlobeNewswire Inc.
The Truth About Illumina Inc.: Is This Genomics Giant Still Worth Your Money? - AD HOC NEWS
Illumina (NASDAQ:ILMN) Sets New 52-Week HighHere's What Happened - MarketBeat
Illumina and Powell Gilbert in love with Lisbon - JUVE Patent
Illumina stock hits 52-week high at 151.35 USD - Investing.com
Life Sciences Tools & Services Stocks Q3 Teardown: Illumina (NASDAQ:ILMN) Vs The Rest - Yahoo Finance
North America Bioinformatics Market Size, Share, Trends, - openPR.com
Illumina Secures CMS Reimbursement for TruSight Oncology Test at $2,989.55 - Intellectia AI
Illumina Gets Medicare Boost for Cancer Test, Shares Climb - Benzinga
Customer Engagement Center - Illumina
Illumina secures CMS reimbursement for cancer genomic test at $2,989 - Investing.com
Illumina Gets Reimbursement For FDA-Approved TruSight Oncology Comprehensive Test, Stock Down - Nasdaq
Press Release - Illumina
Medicare to cover $2,989.55 Illumina genomic cancer test - Stock Titan
Stifel raises Illumina stock price target to $155 on growth outlook - Investing.com
GRAIL Inc.Illumina's Divested Holy Grail (NASDAQ:GRAL) - Seeking Alpha
Illumina Inc. (ILMN) Shares See Target Boost as Analysts See Potential 2026 Upside - Insider Monkey
The Technical Signals Behind (ILMN) That Institutions Follow - Stock Traders Daily
Illumina: What Is Next In This Sequence? (NASDAQ:ILMN) - Seeking Alpha
The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance - Yahoo Finance
2MM: AI Roundup – Lilly and NVIDIA’s $1B AI lab, Illumina’s Billion Cell Atlas, AstraZeneca’s Modella deal, and Claude for Healthcare [Jan 19th, 2026] - 2 Minute Medicine
Is Now An Opportune Moment To Examine Illumina, Inc. (NASDAQ:ILMN)? - 富途资讯
Nordea Investment Management AB Buys 19,519 Shares of Illumina, Inc. $ILMN - MarketBeat
Oncology Research Solutions - Illumina
Stephens Investment Management Group LLC Boosts Holdings in Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. $ILMN Shares Acquired by ASR Vermogensbeheer N.V. - MarketBeat
Illumina Inc. Stock Underperforms Friday When Compared To Competitors - 富途资讯
Illumina, Inc.Common Stock (NQ: ILMN - FinancialContent
Illumina partners with pharma giants to map disease biology at unprecedented scale - Mugglehead Magazine
2026: A turning point for precision health - Illumina
Illumina reports preliminary Q4 revenue of $1.15B - MSN
Illumina's new connected multiomics platform set to boost its stock - MSN
Sumitomo Mitsui Trust Group Inc. Acquires 54,987 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina reports 5% revenue growth in Q4 2025, flat for full year - Investing.com Nigeria
Illumina launches billion cell atlas to boost AI-driven drug discovery - Investing.com Nigeria
Illumina Launches Billion Cell Atlas to Accelerate AI-Driven Drug Development - filmogaz.com
Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery - The Malaysian Reserve
Illumina CEO Sees Big Growth Opportunity in China - marketscreener.com
Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company - marketscreener.com
JPM26: Illumina debuts Billion Cell Atlas to drive AI-driven drug discovery - Pharmaceutical Technology
Illumina Produces Midteens Earnings Growth in 2025, Distancing Itself From the Grail Debacle - Morningstar
Canada Next-Generation Sequencing (NGS) Market Analysis and Forecast, 2025-2035, Featuring Illumina, Oxford Nanopore Technologies, Pacific Bioscience of California, MGI Tech Co., QIAGEN and More - GlobeNewswire
Illumina (NASDAQ:ILMN) Updates Q4 2025 Earnings Guidance - MarketBeat
Illumina launches massive cell atlas to fast-track drug discovery - statnews.com
Press Release: Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 - 富途牛牛
Illumina introduces Billion Cell Atlas, genome-wide genetic perturbation dataset - marketscreener.com
Illumina Inc (ILMN) 財務データ
収益
当期純利益
現金流量
EPS
0.94%
0.33%
大文字化:
|
ボリューム (24 時間):